Explore more publications!

Tech Press Laos: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Tech Press Laos.

Press releases published on April 20, 2026

BlackRock® Canada Announces April Cash Distributions for the iShares® ETFs
Oculis Announces Completion of Last Patient Visit in Phase 3 DIAMOND Program with OCS-01 Eye Drops for the Treatment of Diabetic Macular Edema
NGen Announces $62.7M in World-Leading Advanced Manufacturing Projects
NGen annonce 62,7 M$ en projets de fabrication de pointe de calibre mondial
Makko launches AI-powered 2D game studio with over 40,000 game assets created in Beta
Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases
Nanobiotix annonce de nouvelles données précliniques démontrant une amélioration de la biodisponibilité systémique et la réduction de la toxicité pour des immunothérapies à ADN delivrées par LNP après traitement avec sa technologie de…
Nanobiotix Announces New Preclinical Data Supporting Improved Systemic Bioavailability and Reduced Toxicity for LNP-Delivered DNA Immunotherapy After Pre-Treatment With Nanoprimer Technology
Tencent Invests in Kaspi.kz Alongside Co-Founder & CEO Mikheil Lomtadze and Long-Term U.S. Institutional Investors
Schneider Electric and Deloitte collaborate to drive AI-enabled digital transformation across industrial operations
Reminder: Last Exercise Day for Nicox June 2024 Warrants is June 19, 2026
Rappel : le dernier jour d’exercice pour les Bons de Souscription d’Actions (BSA) Nicox de juin 2024 est le 19 juin 2026
CCUS Hub Study identifies five Asia-Pacific hub sites and welcomes new consortium partners
Ascentage Pharma to Present Four Promising Preclinical Studies Demonstrating the Potential of Combination Therapies at American Association for Cancer Research (AACR) 2026 Annual Meeting

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions